Want to see LLY full AI Analyst Report?
Top Page
Eli Lilly & Co
(NYSE:LLY)
Select Model
Select Model
Rating:76Outperform
Price Target:
$1,322.00
▲(10.53% Upside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by outstanding fundamental momentum (rapid growth, strong profitability, and sharply improving cash generation) and a bullish earnings update with raised guidance. Offsetting factors are elevated leverage and a premium valuation, while technical signals are supportive longer-term but mixed in the near term.
Positive Factors
Sustained Revenue Momentum
Very strong, broad-based top-line growth and an upward guidance revision reflect durable commercial adoption across franchises. Large, diversified revenue pools (cardiometabolic, oncology, immunology) improve predictability of multi-period cash flows and support continued investment in R&D and capacity.
Negative Factors
Elevated Leverage
Material debt build-up increases interest and refinancing exposure and reduces capital allocation flexibility. Higher leverage can constrain opportunistic R&D or M&A spending, raise sensitivity to rate shocks, and amplify downside if growth or cash conversion weakens over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Momentum
Very strong, broad-based top-line growth and an upward guidance revision reflect durable commercial adoption across franchises. Large, diversified revenue pools (cardiometabolic, oncology, immunology) improve predictability of multi-period cash flows and support continued investment in R&D and capacity.
Read all positive factors
Eli Lilly & Co Key Performance Indicators (KPIs)
Any
Revenue by Geography
Maps revenue across countries and regions to show market concentration and diversification. A heavy tilt toward a single market increases vulnerability to local policy or pricing shifts, while broad geographic growth suggests more durable sales and opportunity to offset regional downturns.
Maps revenue across countries and regions to show market concentration and diversification. A heavy tilt toward a single market increases vulnerability to local policy or pricing shifts, while broad geographic growth suggests more durable sales and opportunity to offset regional downturns.
Data provided by:
The Fly
The FlyEli Lilly & Co (LLY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.21T
Dividend Yield0.54%
Average Volume (3M)2.76M
Price to Earnings (P/E)41.7
Beta (1Y)0.53
Revenue Growth49.58%
EPS Growth95.08%
CountryUS
Employees50,000
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)29.85
Shares Outstanding941,357,060
10 Day Avg. Volume2,299,648
30 Day Avg. Volume2,758,695
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)36.37
Price to Sales (P/S)14.81
P/FCF Ratio107.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$1,382.29Price Target Upside15.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)36.4
Revenue Forecast (FY)$88.27B
Eli Lilly & Co Business Overview & Revenue Model
Company Description
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. Thi...
How the Company Makes Money
Eli Lilly primarily makes money by selling patented prescription medicines to healthcare systems and channel intermediaries (e.g., wholesalers, pharmacies, hospitals, and clinics), generating revenue when its products are dispensed or purchased in...
Eli Lilly & Co Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call conveyed strong, broad-based commercial momentum—48% revenue growth, upgraded guidance, major clinical wins (retatrutide, oncology readouts), international strength, and active business development—while acknowledging manageable challenges including U.S. price pressure, guidance seasonality/one-offs, some launch noise (Foundayo) and regulatory/filing uncertainty for retatrutide. Overall, positives (scale, profitability, pipeline progress, access expansions) materially outweigh the operational and pricing headwinds.Positive Updates
Strong Top-Line Revenue Growth
Total revenue grew 48% versus Q2 2025, driven by Key Products which increased by almost $6.8 billion. Full-year revenue guidance raised to $85.0–$87.0 billion (low end +$3B, high end +$2B).
Negative Updates
U.S. Price Pressure and Rebate/Discount Adjustments
Reported U.S. price declined 3% in Q2; excluding changes to rebate/discount estimate adjustments, U.S. price declined ~9% YoY. Management noted prior-period estimate adjustments impacted reported price and revenue dynamics.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Top-Line Revenue Growth
Total revenue grew 48% versus Q2 2025, driven by Key Products which increased by almost $6.8 billion. Full-year revenue guidance raised to $85.0–$87.0 billion (low end +$3B, high end +$2B).
Read all positive updates
Company Guidance
Lilly raised its 2026 guidance, increasing the low end of full‑year revenue by $3.0 billion and the high end by $2.0 billion to a new range of $85.0–$87.0 billion, and now expects a non‑GAAP performance margin of 49.0%–50.5% (up ~2 percentage points) and non‑GAAP EPS of $35.50–$36.50 (a $2.78 midpoint raise before the Q2 acquired IPR&D impact). The upgrade was driven by strong Q2 results — revenue up 48% year‑over‑year, Key Products up nearly $6.8 billion, Oncology/Immunology/Neuroscience medicines up 121%, combined Mounjaro and Zepbound sales of $14.9 billion (contributing $6.3 billion of growth vs. Q2 2025), Q2 non‑GAAP EPS of $8.38 (including $3.03 of acquired IPR&D charges), gross margin of 86.3% (up ~1.3 ppt), and a Q2 non‑GAAP performance margin of 54.8% (up ~9 ppt).Eli Lilly & Co Financial Statement Overview
Summary
Income Statement
92
Very Positive
Balance Sheet
64
Positive
Cash Flow
83
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 79.67B | 65.18B | 45.04B | 34.12B | 28.54B | 28.32B |
| Gross Profit | 66.93B | 54.62B | 36.62B | 27.04B | 21.91B | 21.01B |
| EBITDA | 35.21B | 27.94B | 15.23B | 8.57B | 8.66B | 8.04B |
| Net Income | 26.71B | 20.64B | 10.59B | 5.24B | 6.24B | 5.58B |
Balance Sheet | ||||||
| Total Assets | 142.28B | 112.48B | 78.71B | 64.01B | 49.49B | 48.81B |
| Cash, Cash Equivalents and Short-Term Investments | 8.95B | 7.27B | 3.42B | 2.93B | 2.21B | 3.91B |
| Total Debt | 54.91B | 42.50B | 33.64B | 25.23B | 16.24B | 16.88B |
| Total Liabilities | 108.40B | 85.94B | 64.44B | 53.14B | 38.71B | 39.65B |
| Stockholders Equity | 33.88B | 26.54B | 14.19B | 10.77B | 10.65B | 8.98B |
Cash Flow | ||||||
| Free Cash Flow | 20.05B | 8.97B | 414.30M | -3.15B | 4.60B | 5.39B |
| Operating Cash Flow | 28.08B | 16.81B | 8.82B | 4.24B | 7.59B | 7.37B |
| Investing Cash Flow | -25.10B | -10.97B | -9.30B | -7.15B | -3.76B | -2.87B |
| Financing Cash Flow | 2.61B | -2.21B | 1.23B | 3.50B | -5.41B | -4.13B |
Eli Lilly & Co Technical Analysis
Positive
1196.03
Price Trends
1175.69
Positive
1078.31
Positive
1047.92
Positive
Market Momentum
19.31
Negative
58.25
Neutral
78.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LLY, the sentiment is Positive. The current price of 1196.03 is above the 20-day moving average (MA) of 1193.86, above the 50-day MA of 1175.69, and above the 200-day MA of 1047.92, indicating a bullish trend. The MACD of 19.31 indicates Negative momentum. The RSI at 58.25 is Neutral, neither overbought nor oversold. The STOCH value of 78.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LLY.
Eli Lilly & Co Risk Analysis
Eli Lilly & Co disclosed 16 risk factors in its most recent earnings report. Eli Lilly & Co reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Eli Lilly & Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $658.89B | 30.91 | 25.73% | 1.99% | 8.07% | -7.21% | |
76 Outperform | $1.21T | 41.73 | 92.58% | 0.54% | 49.58% | 95.08% | |
70 Outperform | £186.88B | 24.55 | 21.68% | 1.86% | 4.71% | 21.16% | |
68 Neutral | $290.83B | 23.97 | 29.64% | 3.06% | 2.33% | -4.08% | |
65 Neutral | $470.00B | 73.77 | -136.50% | 2.63% | 10.39% | 68.16% | |
62 Neutral | $375.50B | 118.45 | 6.60% | 2.56% | 4.51% | -80.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
LLY
Eli Lilly & Co
1,255.40
548.18
77.51%
JNJ
Johnson & Johnson
270.24
94.32
53.61%
MRK
Merck & Company
152.55
68.01
80.44%
NVS
Novartis
158.86
34.32
27.56%
ABBV
AbbVie
264.96
60.70
29.72%
GB:AZN
AstraZeneca
12,240.00
473.06
4.02%
Eli Lilly & Co Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Eli Lilly Raises $8.9 Billion in Debt Offering
Positive
May 20, 2026
On May 20, 2026, Eli Lilly and Company completed a multibillion-dollar debt offering, issuing a mix of floating-rate and fixed-rate notes maturing between 2028 and 2066, for net proceeds of about $8.94 billion after underwriting discounts. The off...
Executive/Board ChangesShareholder Meetings
Eli Lilly Shareholders Back Board, Maintain Governance Structure
Neutral
May 7, 2026
At Eli Lilly Co.’s annual meeting of shareholders held on May 4, 2026, investors representing about 90% of outstanding shares cast votes on board elections, executive pay, auditor ratification, and several governance-related proposals. Shar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.